This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Natera (NTRA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Natera (NTRA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Invest in the First Trust Health Care AlphaDEX ETF (FXH)?
by Zacks Equity Research
Sector ETF report for FXH
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FBT
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
by Zacks Equity Research
Sector ETF report for FBT
Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FXH
Should You Invest in the First Trust Health Care AlphaDEX ETF (FXH)?
by Zacks Equity Research
Sector ETF report for FXH
Natera (NTRA) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Natera (NTRA) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
What Makes Natera (NTRA) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does Natera (NTRA) have what it takes to be a top stock pick for momentum investors? Let's find out.
Compared to Estimates, Natera (NTRA) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Natera (NTRA) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Agilon Health (AGL) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Agilon (AGL) delivered earnings and revenue surprises of -46.43% and 0.72%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Bull of the Day: NeoGenomics (NEO)
by Kevin Cook
Small-cap leader in oncology diagnostics is on sale after patent litigation takes a bite
Enhabit (EHAB) Lags Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Enhabit (EHAB) delivered earnings and revenue surprises of -25% and 1.53%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Bull of the Day: NeoGenomics (NEO)
by Kevin Cook
Diagnostic lab companies were hit by new FDA rules but this cancer fighter rebounds under 3X sales
Natera (NTRA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Natera (NTRA) delivered earnings and revenue surprises of 11.01% and 8.74%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Hold Centene (CNC) Stock for Now
by Zacks Equity Research
Strong membership growth, contract wins, accretive acquisitions and the streamlining of businesses poise Centene (CNC) well for growth.
Natera (NTRA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Natera (NTRA) delivered earnings and revenue surprises of -4.24% and 6.88%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Apollo Medical Holdings, Inc. (AMEH) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Apollo Medical Holdings, Inc. (AMEH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Natera (NTRA) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Natera (NTRA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
HealthEquity (HQY) Surges 10.0%: Is This an Indication of Further Gains?
by Zacks Equity Research
HealthEquity (HQY) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Natera (NTRA) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Natera (NTRA) delivered earnings and revenue surprises of 2.14% and 0.83%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for Natera (NTRA) This Earnings Season?
by Zacks Equity Research
Natera (NTRA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Wall Street Analysts Think Natera (NTRA) Could Surge 82.88%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 82.9% in Natera (NTRA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Natera (NTRA) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Natera (NTRA) delivered earnings and revenue surprises of 11.97% and 1.12%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Pediatrix Medical Group (MD) Misses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Pediatrix Medical Group (MD) delivered earnings and revenue surprises of -24.53% and 4.50%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?